CompoAtlas

FEMINALLYA

Food supplement declared in France, declaration No 2018-1-242

FEMINALLYA is a food supplement declared in France. Status: retiré du marché le 31 January 2024. 5 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
OM QUANTALLYA
Status
Retiré du marché le 31 January 2024
Form
Gélule
Daily dose
3 gélules
Directions for use
1 gélule, 3 fois par jour
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous traitement antihypertenseur, Sous traitement pour la thyroïde, Utilisation prolongée

Declaration 285551, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Achillea millefolium L.Parties aériennesExtrait sec aqueux225 mg
Matricaria chamomilla L.FleurExtrait sec aqueux210 mg
Dioscorea oppositifolia L.RacineExtrait sec hydroalcoolique195 mg
Alchemilla vulgaris L.Parties aériennesExtrait sec aqueux150 mg
Brassica oleracea L.GraineExtrait au CO2 supercritique120 mg
Camellia sinensis (L.) KuntzeFeuilleExtrait sec aqueux120 mg
Citrus aurantium L.Essence (feuille)Distillation60 mg

Additives

E551, Hydroxypropyl Méthyl Cellulose

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Enter to analyse, Shift+Enter for a new line